Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome

Andrologia

Volumn 40, Issue 1, 2008, Pages 44-48

  Saad, F ^a,b   Gooren, L ^c   Haider, A ^a   Yassin, A ^a,b  

^a Bayer Schering ^*  (Germany)

^b GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ageing; Metabolic syndrome; Sexual functioning; Testosterone gel; Testosterone undecanoate

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG FORMULATION; GEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; MALE; METABOLIC SYNDROME X; PENIS ERECTION; PROSTATE; REFERENCE VALUE; SEXUAL DYSFUNCTION; WAIST CIRCUMFERENCE;

AGED; ANDROGENS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 38349016541     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/j.1439-0272.2008.00807.x     Document Type: Article

References (19)

1. Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW (2005) Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2 : 96 103.
2. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW (2001) Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281 : E1172 E1181.
3. Gooren LJ, Bunck MC (2004) Androgen replacement therapy: present and future. Drugs 64 : 1861 1891.
4. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I (2006) The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med 166 : 213 219.
5. Harle L, Basaria S, Dobs AS (2005) Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6 : 1751 1759.
6. Jackson G (2006) The metabolic syndrome and erectile dysfunction: multiple vascular risk factors and hypogonadism. Eur Urol 50 : 426 427.
7. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M, Loukovaara M, Leinonen P, Tuomilehto J (2005) Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 90 : 1550 1556.
8. Kelleher S, Conway AJ, Handelsman DJ (2004) Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89 : 3813 3817.
9. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006a) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91 : 843 850.
10. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB (2006b) Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 176 : 222 226.
11. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149 : 601 608.
12. Nieschlag E (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 65 : 275 281.
13. Nieschlag E, Wang C, Handelsman DJ, Swerdloff RS, Wu F, Einer-Jensen N, Waites G (1992) Guidelines for the Use of Testosterone in Men. World Health Organization, Geneva.
14. Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A (2004) Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 6 : 208 215.
15. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89 : 5429 5434.
16. Strain G, Zumoff B, Rosner W, Pi-Sunyer X (1994) The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab 79 : 1173 1176.
17. Vermeulen A, Kaufman JM, Giagulli VA (1996) Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81 : 1821 1826.
18. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89 : 2085 2098.
19. Zitzmann M, Faber S, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91 : 4335 4343.